Clinical Trials Logo

Metastatic Neuroendocrine Tumors clinical trials

View clinical trials related to Metastatic Neuroendocrine Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT00610129 Completed - Clinical trials for Neuroendocrine Tumors

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

Start date: January 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test a new drug for neuroendocrine tumors. We think that this new drug may help control your tumor. MK-0646 is a monoclonal antibody. An antibody is a protein that is able to attach to specific target on cancer cells. This target helps the cancer cells grow and divide. By attaching to the target, it may stop the cancer cells from further growth and dividing. This study will help find out if MK-0646 is a helpful drug when taken in patients with neuroendocrine tumor. This study is a phase 2 study. The purpose of a phase 2 study is to find out what effects, good and/or bad, MK-0646 has on metastatic neuroendocrine tumors.

NCT ID: NCT00590343 Completed - Clinical trials for Metastatic Neuroendocrine Tumors

Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

PTK787
Start date: November 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine if PTK787/ZK222584 (vatalanib) will stabilize or decrease rising biochemical markers along with progressive disease or syndrome symptoms in patients with metastatic neuroendocrine tumors.